Shire Pharmaceuticals Group plc sales and marketing update

Health Canada reinstated the marketing authorization for ADHD drug Adderall XR from SHP on the recommendation of the New Drug Committee (NDC). In February, Health Canada told SHP to stop selling Adderall XR because of U.S. post-marketing reports of sudden deaths in pediatric patients (see BioCentury, Feb. 14). ...